AC Immune (NASDAQ:ACIU) Posts Earnings Results, Misses Expectations By $0.05 EPS

Key Points

• AC Immune reported a quarterly EPS of ($0.25), which missed the consensus estimate of ($0.18) by ($0.07).
• The company has a negative return on equity of 44.60% and a negative net margin of 177.79%.
• Brokerages have reacted by upgrading AC Immune's rating to "buy," although HC Wainwright reduced its target price from $16.00 to $12.00.

AC Immune (NASDAQ:ACIU - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.05), Zacks reports. The company had revenue of $1.65 million for the quarter, compared to analysts' expectations of $1.98 million. AC Immune had a negative return on equity of 49.35% and a negative net margin of 174.94%.

AC Immune Price Performance

NASDAQ ACIU traded up $0.06 during mid-day trading on Friday, hitting $2.14. The company's stock had a trading volume of 97,918 shares, compared to its average volume of 163,494. AC Immune has a 52-week low of $1.43 and a 52-week high of $3.98. The stock's fifty day simple moving average is $2.07 and its two-hundred day simple moving average is $2.06. The firm has a market capitalization of $214.88 million, a P/E ratio of -3.69 and a beta of 1.65.

Analysts Set New Price Targets

Several brokerages have issued reports on ACIU. Wall Street Zen raised shares of AC Immune from a "hold" rating to a "buy" rating in a research note on Tuesday, May 13th. HC Wainwright decreased their price objective on shares of AC Immune from $16.00 to $12.00 and set a "buy" rating on the stock in a research report on Thursday, May 1st.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in AC Immune stock. Acadian Asset Management LLC boosted its holdings in AC Immune (NASDAQ:ACIU - Free Report) by 87.1% during the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 371,177 shares of the company's stock after buying an additional 172,796 shares during the period. Acadian Asset Management LLC owned approximately 0.37% of AC Immune worth $679,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 51.36% of the company's stock.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.